Cardiovascular Disease I

CV1

POST-AMI DRUG THERAPY PERSISTENCE AND RISK OF REINFARCTION IN A MEDICAID POPULATION

Shaya FT, Gu A

University of Maryland School of Pharmacy, Baltimore, MD, USA

CV2

COST-EFFECTIVENESS OF ROSUVASTATIN VERSUS ATORVASTATIN, SIMVASTATIN, AND PRAVASTATIN FROM A CANADIAN HEALTH CARE PERSPECTIVE

Costa-Scharplatz M1, Beamer B2, Frial T2, Gandhi SK3

1AstraZeneca, Södertälje, Sweden, 2AstraZeneca, Mississauga, ON, Canada, 3AstraZeneca, LP, Wilmington, DE, USA

CV3

DO DIFFERENCES IN DOSE IMPACT ADHERENCE TO SINGLE-PILL AMLODIPINE/ATORVASTATIN VERSUS 2-PILL AMLODIPINE AND ATORVASTATIN?

Tang SSK1, Patel BV2, Leslie RS2, Thiebaud P2, Nichol MB3, Solomon HA1, Trainer JB1, Foody JM4

1Pfizer Inc, New York, NY, USA, 2MedImpact Healthcare Systems, Inc, San Diego, CA, USA, 3University of Southern California, Los Angeles, CA, USA, 4Yale University, New Haven, CT, USA

CV4

BENEFIT/RISK OF IRBESARTAN/HYDROCHLOROTHIAZIDE AS FIRST-LINE TREATMENT OF SEVERE HYPERTENSION

Lapuerta P1, Gomez A2, Franklin S3

1Bristol-Myers Squibb, Princeton, NJ, USA, 2Bristol-Myers Squibb, Hopewell, NJ, USA, 3University of California at Irvine, Los Angeles, CA, USA

Economics of Diabetes

ED1

COST-EFFECTIVENESS OF INSULIN DETEMIR VERSUS NPH FOR TYPE 1 DIABETES PATIENTS IN A GERMAN SETTING. A MODELING EVALUATION BASED UPON RESULTS FROM A META-ANALYSIS.

Kotchie R1, Scheijbeler H1, Aagren M2, Nielsen S2, Valentine WJ3, Goodall G3

1IMS Health, London, UK, 2Novo Nordisk A/S, Virum, Denmark, 3IMS Health, Basel, Switzerland

ED2

LONG-TERM COST-UTILITY ANALYSIS OF INSULIN ASPART (NOVORAPID®) VERSUS HUMAN SOLUBLE INSULIN IN TYPE 2 DIABETES PATIENTS IN THE GERMAN SETTING

Goodall G1, Valentine WJ1, Townsend C2, Kotchie R3, Nielsen S2, Erny-Albrecht K1

1IMS Health, Basel, Switzerland, 2Novo Nordisk A/S, Virum, Denmark, 3IMS Health, London, UK

ED3

DIFFERENCES IN HEALTH RELATED RESOURCE USE IN THE 6 MONTHS PRIOR TO AND AFTER INSULIN INITIATION IN PATIENTS WITH TYPE 2 DIABETES IN GERMANY AND UK: DATA FROM THE INSTIGATE STUDY

Timlin L1, Tynan A1,Simpson A1, Jones S2, Liebl A3

1Eli Lilly and Company Limited, Surrey, UK, 2The James Cook University Hospital, Middlesborough, UK, 3Fachklinik Bad Heilbrunn, Bad Heilbrunn, Germany

ED4

THE RELATIVE COST EFFECTIVENESS OF SWITCHING TO INSULIN GLARGINE VERSUS NPH INSULIN IN INSULIN NAIVE AND NON INSULIN NAIVE TYPE 2 DIABETES PATIENTS USING UK REAL LIFE DATA

McEwan P1, Mehin N2, Tetlow AP3, Sharplin P3

1Cardiff University, Cardiff, South Glamorgan, UK, 2sanofi-aventis, Paris, France, 3Cardiff Research Consortium, Cardiff, South Glamorgan, UK

Methods & Concepts

MC1

ASSESSING THE GENERALISABILITY OF COST EVALUATION RESULTS USING THE EUCLIDEAN METRIC AND PRINCIPAL COMPONENTS ANALYSIS: LESSON FROM A HIGH-COST INNOVATION IN ONCOLOGY

Perrier L1, Pommier P1, Carrère MO2, Sylvestre Baron P3

1Léon Bérard Cancer Centre, Lyon, France, 2University of Lyon, Lyon, France, 3University of Lyon, Ecully, France

MC2

BAYESIAN MODELING OF RESOURCE USE ALONGSIDE MULTINATIONAL RANDOMISED CLINICAL TRIALS

Gauthier A1, Manca A2, Anton SF3, Dewberry H4

1i3 Innovus, Uxbridge, Middlesex, UK, 2University of York, York, UK, 3Boehringer-Ingelheim, Ridgefield, CT, USA, 4Boehringer Ingelheim Limited, Bracknell, Berkshire, UK

MC3

THE DEVELOPMENT OF AN INCREMENTAL WILLINGNESS TO PAY CURVE DERIVED FROM A DISCRETE CHOICE EXPERIMENT

Regier DA1, Marra CA2, Ryan M1

1University of Aberdeen, Aberdeen, Scotland, UK, 2University of British Columbia, Vancouver, BC, Canada

MC4

COMPARISON OF THREE INSTRUMENTS ASSESSING THE QUALITY OF ECONOMIC EVALUATIONS

Gerkens S, Crott R, Beguin C, Closon MC, Horsmans Y

Université Catholique de Louvain, Brussels, Belgium

Patient Reported Outcomes I

PR1

RECOMPUTING VALUES FOR EQ-5D IN ACCORDANCE WITH NICE APPRAISAL GUIDANCE

Kind P

University of York, York, UK

PR2

NON-PERSISTENT USE OF ORAL ANTIDIABETIC DRUGS LEADS TO 20% DECREASED CHANCE OF HBA1C GOAL-ATTAINMENT IN DAILY CLINICAL PRACTICE

Koerselman J1, van der Bij S1, Erkens JA1, Kessabi S2, Groot MT3, Penning-van Beest FJ1, Herings RM1

1PHARMO Institute, Utrecht, Utrecht, The Netherlands, 2Novartis Pharma AG, Basel, Switzerland, 3Novartis Pharma B.V, Arnhem, The Netherlands

PR3

PATIENTS', PARENTS', AND PHYSICIANS' RISK-BENEFIT TRADE-OFF PREFERENCES FOR CROHN'S DISEASE TREATMENTS

Johnson FR1, Ozdemir S1, Mansfield C1, Hauber AB1, Hass SL2, Siegel CA3, Sands BE4, Miller DW2

1RTI International, RTP, NC, USA, 2Elan Pharmaceuticals Inc, San Diego, CA, USA, 3Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA, 4Massachusetts General Hospital, Boston, MA, USA

PR4

BACK PAIN IN GERMANY: ARE THERE DIFFERENCES CONCERNING HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS TREATED ACCORDING TO GUIDELINES, GUIDELINE INDEPENDENT AND PATIENT SELF-TREATMENT?

Breitscheidel L1, Stridde E2, Kreyenberg K1, Benter U1, Eichmann F1

1Kendle GmbH, Munich, Germany, 2Pfizer Pharma GmbH, Karlsruhe, Germany

Cancer

CN1

USING THE FACT-NEUROTOXICITY TO EVALUATE QUALITY OF LIFE IN CANCER PATIENTS FROM ACROSS THE GLOBE

Eremenco S, Du H, Arnold B, Herzberg T, Cella D

Evanston Northwestern Healthcare, Evanston, IL, USA

CN2

DEVELOPMENT AND VALIDATION OF OPTIMALLY WEIGHTED MEASURES OF GLOBAL HEALTH-RELATED QUALITY OF LIFE (QOL) AND UTILITY BASED ON A CANCER-SPECIFIC QOL INSTRUMENT

Grimison PS, Simes RJ, Stockler MR

NHMRC Clincial Trials Centre, University of Sydney, CAMPERDOWN, NSW, Australia

CN3

EFFECTIVENESS OF EPOETIN ALPHA VERSUS DARBEPOETIN IN CHEMOTHERAPY-INDUCED ANAEMIA IN THE GERMAN SETTING

Ezzat N1, Brüggenjürgen B2, Willich SN2

1Alpha Care GmbH, Celle, Germany, 2Charite University Medical Center, Berlin, Germany

CN4

COST-EFFECTIVENESS OF PEGYLATED LIPOSOMAL DOXORUBICIN VS. CONVENTIONAL DOXORUBICIN IN AVOIDANCE OF CARDIOTOXICITY FOR METASTATIC BREAST CANCER IN THE FIRST TREATMENT YEAR

Singer ME1, Sandor DW2, Reardon G3

1Case Western Reserve University School of Medicine, Cleveland, OH, USA, 2Touro University College of Medicine, Hackensack, NJ, USA, 3Informagenics, LLC, Worthington, OH, USA

Economic Studies I

ES1

INCREMENTAL DIFFERENCES IN RESOURCE UTILIZATION AND COSTS OF TREATING PERSONS INFECTED WITH HIV IN A LOW SOCIOECONOMIC NEIGHBORHOOD

Johnston KM1, Levy A1, Lai C2, Briggs A3, Kerr T2, Montaner JS2, Tyndall M1

1University of British Columbia, Vancouver, BC, Canada, 2British Columbia Centre for Excellence in HIV/AIDS Research, Vancouver, BC, Canada, 3University of Glasgow, Glasgow, UK

ES2/
PMH44

COSTS AND OUTCOMES OF ATYPICAL ANTIPSYCHOTICS FOR THE TREATMENT OF ACUTE SCHIZOPHRENIA

ES3

COST-EFFECTIVENESS OF FIRST EYE CATARACT SURGERY IN ELDERLY WOMEN: A RANDOMISED CONTROLLED TRIAL

Sach TH1, Foss AJ2, Gregson RM2, Zaman A2, Osborn F2, Masud T2, Harwood RH2

1University of Nottingham, Nottingham, UK, 2Nottingham University Hospitals NHS Trust, Nottingham, UK

ES4/
PSU2

THE RELATIVE COST-EFFECTIVENESS OF THE FENTANYL HCL PATIENT-ACTIVATED TRANSDERMAL SYSTEM (ITS) IN ACUTE POST-OPERATIVE PAIN MANAGEMENT (POPM) IN GREECE

Yfantopoulos I1, Papanicolaou S2, Papagianopoulou V1, Van Bellinghen LA3, Annemans L4

1University of Athens, Athens, Greece, 2Janssen-Cilag Pharmaceutical SACI, Athens, Greece, 3IMS HEOR, Brussels, Belgium, 4Ghent University, Ghent, Belgium

Patient Reported Outcomes II

PR5

VALIDATION OF POMS QUESTIONNAIRE IN POSTMENOPAUSAL WOMEN

Yu H1, Wyrwich K2, Bobula J1

1Wyeth Research, Collegeville, PA, USA, 2Saint Louis University, St. Louis, MO, USA

PR6

PATIENT CHARACTERISTICS IMPACTING QUALITY OF LIFE (EQ-5D) OF FEMALES WITH STRESS URINARY INCONTINENCE SYMPTOMS

Tincello D1, Sculpher M2, Tunn R3, Quail D4, Timlin L4, Manning M5

1University of Leicester, Leicester, UK, 2University of York, York, UK, 3St Hedwig Hospitals, Berlin, Germany, 4Eli Lilly and Company Limited, Surrey, UK, 5Lilly Deutschland, BadHomburg, Germany

PR7

PATIENT'S PREFERENCES FOR OSTEOPOROSIS DRUG TREATMENT: A DISCRETE CHOICE EXPERIMENT

De Bekker-Grob EW, Essink-Bot ML, Meerding WJ, Pols HAP, Koes BW, Steyerberg EW

Erasmus MC, Rotterdam, The Netherlands

PR8

EVALUATION OF IMPROVEMENT IN HEALTH-RELATED QUALITY OF LIFE USING ORAL MESALAZINE ALONE OR IN COMBINATION WITH A MESALAZINE ENEMA IN ACTIVE ULCERATIVE COLITIS: RESULTS FROM A RANDOMISED CONTROLLED TRIAL

Nielsen SK1, Currie CJ2, Connolly MP1, Bhatt A1

1Ferring International Center, Saint-Prex, Switzerland, 2Cardiff University, Cardiff, UK

Surgery

SU1

COST-EFFECTIVENESS OF CYCLOOXYGENASE-2 INHIBITOR PARECOXIB COMPARED TO OPIOIDS AFTER NONCARDIAC SURGERY IN THE UK

Remák E1, Muszbek N2, Manson SC3, Zlateva G4, Chen C4

1United Biosource Corporation, Budapest, Hungary, 2UnitedBiosource Corporation, London, UK, 3United BioSource Corporation, London, UK, 4Pfizer Inc, New York, NY, USA

SU2

MICRO-COSTING OF SURGICAL PROCEDURES RELATED TO INTRACEREBRAL HAEMORRHAGE IN A UK HEALTH CARE SETTING

Manson SC1, De Cock E2, Jenkins AJ3, Twena N4

1United BioSource Corporation, London, UK, 2United BioSource Corporation, Barcelona, Spain, 3Newcastle General Hospital, Newcastle upon Tyne, UK, 4Novo Nordisk Ltd, Crawley, West Sussex, UK

SU3

NINE YEAR FOLLOW UP OF BIRMINGHAM HIP RESURFACING IN CONTEXT OF SURVIVAL AND COMPLICATIONS.

Aulakh TS, Robinson EV, Richardson JB

RJAH Orthopaedic Hospital, Oswestry, Shropshire, UK

SU4

THE COST-EFFECTIVENESS OF TITANIUM CAGE VERSUS FEMORAL RING ALLOGRAFT IN CIRCUMFERENTIAL LUMBAR FUSION: A RANDOMISED CONTROLLED TRIAL

Sach TH1, Steele NA2, Hegarty J2, Soegaard R3, Freeman BJ2

1University of Nottingham, Nottingham, UK, 2Nottingham University Hospitals NHS Trust, Nottingham, UK, 3University of Aarhus, Aarhus, Denmark

Diabetes

DB1

IMPACT OF ROSIGLITAZONE THERAPY ON THE LIPID PROFILE AND LIPID-LOWERING TREATMENT IN TYPE 2 DIABETES PATIENTS

Suh DC1, Huang J1, Nocea G2, Yin D3, Krishnarajah G3

1Rutgers University, Piscataway, NJ, USA, 2MSD Spain, Madrid, Spain, 3Merck & Co., Inc, Whitehouse Station, NJ, USA

DB2

COMPARING BRITISH AND GERMAN DIABETES GUIDANCE WITH RESPECT TO LONGTERM OUTCOMES AND ASSOCIATED COSTS: RESULTS FROM THE EAGLE DIABETES SIMULATION MODEL

Mueller E1, Huppertz E2, Stridde E3

1Analytica International, Loerrach, Germany, 2Consultant HE&RO, Niedererbach, Germany, 3Pfizer Pharma GmbH, Karlsruhe, Germany

DB3

CLINICAL AND PATIENT REPORTED OUTCOMES OVER THE FIRST 6 MONTHS OF INSULIN THERAPY IN PATIENTS WITH TYPE 2 DIABETES IN GERMANY AND UK: DATA FROM THE INSTIGATE STUDY

Timlin L1, Tynan A1, Simpson A1, Liebl A2, Jones S3

1Eli Lilly and Company Limited, Surrey, UK, 2Fachklinik Bad Heilbrunn, Bad Heilbrunn, Germany, 3The James Cook University Hospital, Middlesborough, UK

DB4

TREATMENT ADHERENCE AND BARRIERS TO ADHERENCE ARE ASSOCIATED WITH GLYCEMIC CONTROL AND EXPERIENCE OF HYPOGLYCEMIA AMONG PATIENTS WITH TYPE-2 DIABETES MELLITUS (T2DM) ON ORAL ANTI-HYPERGLYCEMIC AGENTS (OHA) IN EUROPE

Alvarez-Guisasola F1, Martin Castillo F2, Krishnarajah G3, Lyu R4, Mavros P4, Yin D4

1Centro de Salud La Calzada II, Gijón, Spain, 2Hospital General de Móstoles, Madrid, Spain, 3Merck & Co, Whitehouse Station, NJ, USA, 4Merck & Co., Inc, Whitehouse Station, NJ, USA

Economics of Cancer

EC1

RESOURCE USE AND COST OF DIAGNOSTIC WORKUP OF WOMEN WITH SUSPECTED BREAST CANCER

Lee DW1, Stang PE2, Goldberg GA3, Haberman M4

1GE Healthcare, Waukesha, WI, USA, 2Independent Consultant, Blue Bell, PA, USA, 3i3 Innovus, Santa Monica, CA, USA, 4Thomson Medstat, Washington, DC, USA

EC2

AN ECONOMIC EVALUATION OF DASATINIB AS A TREATMENT FOR CHRONIC PHASE CHRONIC MYELOID LEUKAEMIA IN SCOTLAND

Taylor MJ1, Minda K2, Cerri KH3, Davis C4, Kan HJ5, Ray S6

1University of York, York, UK, 2Bristol-Myers Squibb Pharmaceuticals, Uxbridge, UK, 3Bristol-Myers Squibb International Corporation, Braine l'Alleud, Braine l'Alleud, Belgium, 4Bristol-Myers Squibb, Wallingford, CT, USA, 5Bristol Myers Squibb, Wallingford, CT, USA, 6Bristol-Myers Squibb Pharmaceuticals, Wallingford, CT, USA

EC3

COST-MINIMIZATION ANALYSIS OF CAPECITABINE + OXALIPLATIN (XELOX) VS. INFUSIONAL 5-FU/LV + OXALIPLATIN (FOLFOX-6) AS FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER (MCRC) IN THE FRENCH SETTING

Perrocheau G1, Ducreux M2, Hebbar M3, Ychou M4, Lledo G5, Conroy T6, Faroux R7, Douillard JY8, Pacull A9

1Centre René Gauducheau, Saint-Herblain, France, 2Institut Gustave Roussy, Villejuif, France, 3CHU, Lille, France, 4Centre Val d’Aurelle, Montpellier, France, 5Clinique Saint-Jean, Lyon, France, 6Centre Alexis Vautrin – Centre regional de Lutte contre le Cancer, Vandoeuvre les Nancy, France, 7Centre Hospitalier Départemental – Les Oudairies, La Roche sur Yon, France, 8Centre René Gauducheau, Nantes, France, 9Roche, Neuilly-sur-Seine, France

EC4

COST-EFFECTIVENESS AND COST-UTILITY OF RITUXIMAB MAINTENANCE THERAPY FOR PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA IN FRENCH SETTING

Pacull A1, Coudray-Omnes C1, Brice P2, Deconinck E3, Le Pen C4, Miadi-Fargier H5

1Roche, Neuilly-Sur-Seine, France, 2Saint-Louis Hospital, Paris, France, 3INSERM U-645 Université de Franche-Comté CHU Jean Minjoz IFR 133, Besançon, France, 4Dauphine University, Paris, France, 5AREMIS - aegisnet, Neuilly sur Seine, France

Health Care Use & Policy Studies

HP1

HEALTH SYSTEM CORRELATES OF RECEIPT OF RADIATION AFTER BREAST CONSERVING SURGERY IN LOW-INCOME MEDICAID-ENROLLED WOMEN

Anderson RT1, Balkrishnan R2

1Wake Forest University School of Medicine, Winston Salem, NC, USA, 2The Ohio State University College of Pharmacy, Columbus, OH, USA

HP2

ASSOCIATIONS BETWEEN NEGATIVE SYMPTOMS, SERVICE USE, AND COSTS FOR PATIENTS WITH SCHIZOPHRENIA IN FIVE EUROPEAN COUNTRIES

Leeuwenkamp O1, Knapp M2, McCrone P3

1NV Organon, Molenstraat, Oss, The Netherlands, 2London School of Economics, London, UK, 3King's College London, London, UK

HP3

ASSESSING THE IMPACT OF A NATIONAL DRUG BENEFIT PROGRAM ON THE USE OF GENERIC DRUGS AND DIFFERENT THERAPEUTIC CLASSES

Zhang JX1, Yin W1, Sun SX2, Lee KY2, Meltzer DO1, Alexander GC1

1University of Chicago, Chicago, IL, USA, 2Walgreens Health Services, Deerfield, IL, USA

HP4

PROMOTING A DRUG'S HEALTH ECONOMIC ADVANTAGES IN MEDICAL JOURNAL ADVERTISING IN THE U.S.: A REVIEW OF 3,500 ADS FROM 1990-2006

Neumann PJ, Palmer JA, Timm AR

Tufts-New England Medical Center, Boston, MA, USA

Musculoskeletal Disease

MD1

IMPACT OF ANTI-TUMOR NECROSIS FACTORS ON HEALTHCARE RESOURCE UTILIZATION IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES

Tang B1, Rahman MI1, Stephenson JJ2, Quimbo RA2, Thompson HC1, Naim A1, Dabbous O1

1Centocor, Inc, Horsham, PA, USA, 2HealthCore Inc, Wilmington, DE, USA

MD2

ECONOMIC CONSEQUENCES OF PROVIDING RITUXIMAB AS A TREATMENT ALTERNATIVE FOR RHEUMATOID ARTHRITIS IN THE NETHERLANDS

Pompen M1, Diamantopoulos A2, Kievit W3, Moers R4, Kielhorn A5

1Roche Netherland BV, Woerden, The Netherlands, 2IMS Health, London, UK, 3Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands, 4Roche Nederland BV, Woerden, The Netherlands, 5F. Hoffmann-La Roche AG, Basel, Switzerland

MD3

CHANGES IN BODYWEIGHT AND ASSOCIATED DOSING REQUIREMENTS FOR RHEUMATOID ARTHRITIS PATIENTS RECEIVING INFLIXIMAB - RESULTS FROM ANALYSIS OF THE BRITISH SOCETY FOR RHEUMATOLOGY'S BIOLOGICS REGISTER (BSRBR)

Gibbons CJ, Morris J, Abhyankar B

Schering-Plough, Welwyn Garden City, UK

MD4

COST-EFFECTIVENESS OF BONE DENSITOMETRY SCREENING COMBINED WITH ALENDRONATE THERAPY FOR THOSE WHO HAVE OSTEOPOROSIS

Hiligsmann M, Bruyère O, Ethgen O, Reginster JY

University of Liège, Liège, Belgium

Cardiovascular Disease II

CV5

FONDAPARINUX (FOND) VERSUS ENOXAPARIN (ENOX) FOR PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLIC EVENTS (VTE) IN PATIENTS UNDERGOING MAJOR ORTHOPEDIC SURGERY OF THE LOWER LIMBS (MOSLL) IN GERMANY: ECONOMIC EVALUATION FROM THE HOSPITAL PERSPECTIVE

Schaedlich P1, Briswalter S2, Brecht J3

1Informed, Itzehoe, Germany, 2GlaxoSmithKline, Munich, Germany, 3Informed, Ingolstadt, Germany

CV6

SIROLIMUS-ELUTING VERSUS BARE-METAL CORONARY STENTS: 18-MONTH CLINICAL AND ECONOMIC OUTCOMES OF A CONTROLLED STUDY FOR THE REDUCTION OF CORONARY RESTENOSIS

McBride D, Brüggenjürgen B, Roll S, Willich SN

Charité University Medical Center, Berlin, Germany

CV7

COMPARISON OF THE COST-EFFECTIVENESS OF SEROLIMUS-ELUTING VERSUS BARE-METAL STENTS IN RELATION TO PATIENT CORONARY ARTERY DISEASE STATUS

Brüggenjürgen B, McBride D, Roll S, Reinhold T, Willich SN

Charité University Medical Center, Berlin, Germany

CV8

THE COST-EFFECTIVENESS (COST-UTILITY) OF EPROSARTAN IN HYPERTENSIVE PATIENTS WITH CEREBROVASCULAR DISEASE IN BELGIUM, GERMANY, SPAIN, UK, AND SWEDEN

Schwander B1, Lindgren P2, Gradl B3

1Analytica International, Loerrach, Germany, 2I3 innovus, Stockholm, Sweden, 3Solvay Pharmaceuticals GmbH, Hannover, Germany

Economic Studies II

ES5

DOES ARTHROSCOPIC ACROMIOPLASTY PROVIDE ANY ADDITIONAL VALUE IN THE TREATMENT OF SHOULDER IMPINGEMENT SYNDROME? A TWO-YEAR RANDOMIZED CONTROLLED TRIAL

Aronen PI

University of Helsinki, Helsinki, Finland

ES6

COST COMPARISON BETWEEN HAEMODIALYSIS AND PERITONEAL DIALYSIS IN NORWAY FOR PATIENTS WHO CAN USE EITHER TREATMENT MODALITY

Nyhus K, Kristensen FKO, Merméjean P, Sverre JM

PharmEcon, Asker, Akershus, Norway

ES7

ASSESSMENT OF LONG-RUN ECONOMIC BENEFITS ASSOCIATED WITH IN-VITRO FERTILIZATION (IVF) FUNDING DECISIONS: A SIMPLIFIED LIFETIME TAX CALCULATION

Connolly MP1, Hoorens S2, Gallo F2, Ledger W3

1Ferring International Center, Saint-Prex, Switzerland, 2RAND Europe, Cambridge, UK, 3University of Sheffield, Sheffield, UK

ES8

COST-EFFECTIVENESS OF DARUNAVIR/R IN HIGHLY TREATMENT-EXPERIENCED HIV/AIDS PATIENTS IN DIFFERENT EUROPEAN HEALTH CARE SETTINGS

Moeremans K1, Annemans L2, Smets E3, Wyffels V4, Lothgren M5, Allegri G6

1IMS HEOR, Brussels, Belgium, 2Ghent University, Gent, Belgium, 3Johnson & Johnson Pharmaceutical Services, Inc, Beerse, Belgium, 4Janssen Cilag NV, Berchem, Belgium, 5JANSSEN-CILAG, Sollentuna, Sweden, 6TIBOTEC a division of JANSSEN-CILAG SpA Italy, Cologno Monzese, Italy

Economics of Neurological Disease

ND1

COST-EFFECTIVENESS OF INTRATHECAL BACLOFEN THERAPY VERSUS CURRENT THERAPIES IN DISABLED SPASTICITY

Beresniak A1, Bensmail D2, Ward A3, Wissel J4, Motta F5, Saltuari L6, Lissens J7, Cros S7

1Data Mining International, Geneva, Switzerland, 2Raymond Poincare Hospital, Garches, France, 3University Hospital of North Staffordshire, Burslem, UK, 4Kliniken Beelit Gmbh, Beelitz, Germany, 5Ospedale dei bambini, Milano, Italy, 6LKH Hochzirl, Zirl, Austria, 7Medtronic International, Tolochenaz, Switzerland

ND2

MODELING THE COST-EFFECTIVENESS OF A NEW TREATMENT FOR MS (NATALIZUMAB) COMPARED TO CURRENT STANDARD PRACTICE IN SWEDEN

Kobelt G1, Berg J2, Lindgren P2, Hillert J3

1European Health Economics, Speracedes, France, 2i3 Innovus, Stockholm, Sweden, 3Karolinska Institute, Stockholm, Sweden

ND3

MODELING TREATING MULTIPLE SCLEROSIS WITH DISEASE MODIFYING DRUGS USING DISCRETE EVENT SIMULATION

Guo S1, Copur D1, Ward A1, Bennett R2, Al-Sabbah A2, Meletiche DM2, Caro JJ1

1Caro Research Institute, Concord, MA, USA, 2EMD Serono, Inc, Rockland, MA, USA

ND4

COST-EFFECTIVENESS OF A LIDOCAINE PLASTER RELATIVE TO PREGABALIN IN THE TREATMENT OF POST-HERPETIC NEURALGIA IN SCOTLAND

Dakin HA1, Nuijten MJC2, Poulsen Nautrup B3, Liedgens H3

1Abacus International, Bicester, Oxfordshire, UK, 2Erasmus University, Rotterdam, The Netherlands, 3Grünenthal GmbH, Aachen, Germany

Respiratory Disease

RS1

A RETROSPECTIVE, OBSERVATIONAL STUDY COMPARING OUTCOMES OF ASTHMA TREATMENT WITH FIXED COMBINATIONS OF INHALED CORTICOSTEROID AND LONG-ACTING â2-AGONIST (ICS/LABA) IN REAL-LIFE PRACTICE

Thomas M1, Von Ziegenweidt J2, Wirén A3, Ståhl E3, Price D1

1University of Aberdeen, Aberdeen, UK, 2Respiratory Research Ltd, Aberdeen, UK, 3AstraZeneca, Lund, Sweden

RS2

RESOURCE USE AND FINANCIAL IMPACT OF CRITICALLY ILL PATIENTS WITH PNEUMONIA AND RESPIRATORY FAILURE IN THE UNITED STATES

Mank J1, Chalfin DB2, Caeser M1

1ALTANA Pharma AG, Konstanz, Germany, 2Analytica International, Inc, New York, NY, USA

RS3

IMPACT OF SOCIO-ECONOMIC FACTORS ON PATIENTS' KNOWLEDGE OF THEIR CONDITION, INVOLVEMENT IN TREATMENT DECISIONS AND THE SUBSEQUENT COMPLIANCE WITH THEIR TREATMENT REGIMEN

Palm M1, Higgins V2, Lawson R1, Piercy J3

1Adelphi Group Products, Bollington, Cheshire, UK, 2Adelphi Group Products, New York, NY, USA, 3Adelphi Group, Bollington, UK

RS4

ASTHMA COSTS AND UTILIZATION IN A MANAGED CARE ORGANIZATION

Hay JW1, Zeiger RS2, Contreras RX3, Chen W3, Quinn VP3, Seal B4, Schatz MX2

1University of Southern California, Los Angeles, CA, USA, 2Kaiser Permanente Medical Center, San Diego, CA, USA, 3Kaiser Permanente Southern California Region, Pasadena, CA, USA, 4Sanofi-Aventis, Bridgewater, NJ, USA